Kathryn Ruth Kendall, M.A. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4515 Tower Ave, Saint Bernard, OH 45217 Phone: 513-482-7158 |
News Archive
Xencor, Inc., a company using its proprietary Protein Design Automation (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies.
More standardised methods are needed for the extemporaneous preparation of paediatric medicines, indicates a doctoral dissertation examined at the University of Eastern Finland. Hospital pharmacies modify adult medicines for children when there are no suitable paediatric medicines available. Medicines intended for adults can be modified for children into oral suspensions, oral powders or capsules the contents of which are emptied for use.
Boston Scientific Corporation today announced the market launch and first implants of its TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries. The TAXUS Element Stent System is the Company's third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system. It received CE Mark approval last month, which included a specific indication for the treatment of diabetic patients.
A new study finds that a decades-old drug used to treat malaria lowers levels of a biomarker linked to the inherited form of amyotrophic lateral sclerosis, also known as ALS and Lou Gehrig's Disease.
Oral treatments for pulmonary arterial hypertension reduce patients' risk of clinical worsening but have little effect on survival, say the authors of a meta-analysis.
› Verified 6 days ago